Gina Mauro

Vice President of Content, OncLive and Cancer Network
Gina Mauro is your lead editorial contact for OncLive. She joined the company in 2015 and has held various positions on OncLive; she is also the on-air correspondent for OncLive News Network: On Location. Prior to joining MJH Life Sciences, she worked at Gannett as a full-time reporter with the Asbury Park Press. Email: gmauro@onclive.com

Articles

Raludotatug Deruxtecan Shows Activity in Platinum-Sensitive Ovarian Cancer

June 21st 2025

Raludotatug deruxtecan showed promising clinical activity in patients with heavily pretreated, platinum-sensitive ovarian cancer.

Elranatamab Triplet Yields Nearly 100% ORR in Newly Diagnosed Multiple Myeloma

June 16th 2025

Results from dose level G of MagnetisMM-6 found high response rates with an elranatamab triplet in patients with newly diagnosed multiple myeloma.

Consolidation Blinatumomab Improves Efficacy Vs Chemo in Newly Diagnosed BCR::ABL1– B ALL

June 15th 2025

The E1910 trial results showed improved OS and RFS with blinatumomab vs chemotherapy in patients with newly diagnosed BCR::ABL1-negative B ALL.

BGB-16673 Is Safe, Elicits Nearly 85% ORR in Relapsed/Refractory CLL/SLL

June 15th 2025

BGB-16673 showed a favorable safety profile and promising antitumor activity in relapsed/refractory CLL/SLL, with responses seen across baseline mutations.

Early Daratumumab in Patients With Myeloma Experiencing MRD Relapse Delays Clinical Progression

June 15th 2025

PREDATOR-MRD data can serve as proof of concept for larger trials with novel MRD assessment techniques.

Addition of Dasatinib to Induction/Consolidation Fails to Boost Survival in Core-Binding Factor AML

June 14th 2025

Dasatinib added to induction and consolidation, then continued as maintenance, did not improve survival in core-binding factor AML.

Talquetamab/Cetrelimab Leads to Deep, Durable Responses in R/R Multiple Myeloma

June 14th 2025

Talquetamab plus cetrelimab showed safety and efficacy in R/R multiple myeloma, including in patients previously treated with bispecific antibodies.

Venetoclax/DEC-C Is Potential New SOC in Newly Diagnosed AML Ineligible for Intensive Chemo

June 12th 2025

Venetoclax and decitabine-cedazuridine demonstrated complete responses and encouraging survival outcomes in newly diagnosed AML.

Telisotuzumab Vedotin Elicits Responses in c-MET–Overexpressing NSCLC, Regardless of Prior Therapy

June 12th 2025

Telisotuzumab vedotin showed durable responses in c-MET–overexpressing, nonsquamous, EGFR-wildtype NSCLC, regardless of prior platinum or ICI therapy.

UGN-102 Elicits Nearly 80% CR Rate in Recurrent Low-Grade NMIBC

June 9th 2025

UGN-102 showed strong responses in patients with recurrent, intermediate-risk, low-grade non–muscle-invasive bladder cancer, per the phase 3 ENVISION trial.

Epcoritamab Maintains Responses at 3 Years in Relapsed/Refractory LBCL

June 5th 2025

Epcoritamab monotherapy yielded durable remissions and survival benefits in relapsed/refractory LBCL that remained in CR 2 years after starting treatment.

THIO Plus Cemiplimab Shows Activity and Is Safe in ICI-Resistant Advanced NSCLC

June 4th 2025

THIO plus cemiplimab showed tolerability and activity in ICI-resistant advanced NSCLC in the second- and third-line settings.

One-Third of Patients With R/R Myeloma Are Progression Free at ≥5 Years With Cilta-Cel

June 3rd 2025

A single infusion of cilta-cel led to a 5-year PFS in patients with heavily pretreated relapsed/refractory myeloma in long-term follow-up of CARTITUDE-1.

Adjuvant Nivolumab Plus Relatlimab Misses the Mark in Resected Stage III to IV Melanoma

June 3rd 2025

Relatlimab plus nivolumab did not improve RFS over nivolumab alone in resected stage III to IV melanoma, per the final phase 3 RELATIVITY-098 results.

Neoadjuvant Nivolumab Plus Chemo Significantly Improves OS Vs Chemo in Resectable NSCLC

June 3rd 2025

Neoadjuvant nivolumab plus chemo significantly improved OS vs chemo alone in resectable NSCLC, supporting practice-changing potential.

Relacorilant Combo Improves PFS, Trends Toward Superior OS in Platinum-Resistant Ovarian Cancer

June 2nd 2025

Relacorilant plus nab-paclitaxel showed meaningful PFS and OS gains, offering a potential new option for patients with platinum-resistant ovarian cancer.

KEYNOTE-A18 Data Support Pembrolizumab Plus CCRT as New SOC in High-Risk Cervical Cancer

June 2nd 2025

Pembrolizumab plus CCRT showcases sustained survival benefits in high-risk locally advanced cervical cancer.

Addition of Toripalimab to Induction Improves PFS in Nonresectable NSCLC

June 2nd 2025

Adding induction toripalimab to chemotherapy followed by definitive chemoradiotherapy and consolidation therapy reduced risk for disease progression by 74%.

Belantamab Mafodotin Triplet Improves PFS, Responses in R/R Myeloma With High-Risk Cytogenetics

June 2nd 2025

Belantamab mafodotin plus Pd improved PFS and response rates in patients with relapsed/refractory multiple myeloma with high-risk cytogenetics.

Ribociclib Benefit Is Sustained in HR+ Early Breast Cancer Regardless of Age, Menopausal Status

June 1st 2025

Ribociclib plus a nonsteroidal aromatase inhibitor improved iDFS, DDFS, RFS, and DRFS in HR+/HER2– early breast cancer.